7th DDR Inhibitors Summit The Colonnade Hotel, Boston

DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like Roche and Gilead are diving into this therapeutic strategy; biotech companies like Artios and IDEAYA remain dedicated to delivering safe and effective treatments to patients.

The unmet need for cancer therapies reinforces the critical importance for the community to unite at the 7th Annual DDR Inhibitors Summit in Boston, January 2024, to advance first-in-class oncology treatments for patients.

This year’s conference has undergone a renovation to maximize your experience, featuring a new biomarkers pre-conference focus day with the goal of demystifying patient stratification and target ID. Two tracks for the main conference days follow, covering early discovery of next-generation targets and clinical updates.

Join 150 peers in oncology innovation, synthetic lethality, medicinal chemistry, and clinical development, at the exclusive DDR Inhibitors conference – the sole industry-led event providing unmatched depth and insight into your challenges.

Speakers: Alan D’Andrea, Director – Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Alex gaither, Vice President – Biology, Ex Scientia, Alison Karst, Senior Research Scientist – Oncology Biology, Gilead Sciences, Astrid Zimmermann, Director – Oncology Research Unit, Merck KGaA, Charles Sinclair, Senior Director, Head of Translational Sciences, Flagship Pioneering, Daniel Speidel, Managing Director and Co- Founder, Breakpoint Therapeutics, David Mankoff, Associate Director of Education and Training and Scientific Advisory Board Member and Co-founder, University of Pennsylvania, Duncan Hamish, Wright Vice President – Translational Science, Schrodinger Inc, Eeson Rajendra, Director of DDR Biology, Artios Pharma, Hua Gong, SVP – Translational Medicine and Clinical Biomarker, ZaiLaboratory, Ioannis Gounaris, Head of Clinical Development DDR, Merck KGaA, Isabel Jaco, Senior Principal Scientist, Novartis Institutes for BioMedical Research, Jann Sarkaria, Radiation Oncology, Mayo Clinic, Jatinder Mukker, Director – Clinical Pharmacology, EMD Serono, Julian Blagg, Executive Vice President – Drug Discovery, NeoPhore, Katherine Pawelczak, Chief Operating Officer and Vice President – Research, Nerx BioSciences Inc., Kieran Pinto, Research Analyst, Beacon Targeted Therapies, Luke Piggott, Associate Principal Scientist, Debiopharm Research and Manufacturing SA, Marco Maruggi, Principal Scientist, Pfizer, Mark O’Connor, Chief Scientist – Early Oncology Discovery, AstraZeneca, Matthew Wongchenko, Principal Scientific Manager, Genentech, Michal Zimmermann, Director of Cancer Biology, Repare Therapeutics, Oren Gilad, Chief Operating Officer, Aprea Theraputics, Reeja Maskey, Principal Research Scientist, IDEAYA Biosciences, Shailaja Kasibhatla, Senior Vice President, Boundless Bio, Sonia Iyer, Director – Immuno-Oncology Strategy and Translational Medicine, AstraZeneca, Stephen Blakemore, Vice President Translatinal Medicine, Accent Therapeutics, Timothy Yap, Associate Professor – Medical Institute for Applied Cancer Science, MD Anderson Cancer Center, Ulrika Warpman Berglund, CEO, Oxcia, Yong Cang, Chief Scientific Officer and Co-founder, Degron Therapeutics